Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human

Drug Metabolism and Disposition

Volumn 40, Issue 7, 2012, Pages 1345-1356

  Su, Hong ^a   Boulton, David W ^a   Barros, Anthony ^a   Wang, Lifei ^a   Cao, Kai ^a   Bonacorsi, Samuel J ^a   Iyer, Ramaswamy A ^a   Humphreys, W Griffith ^a   Christopher, Lisa J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; 5 HYDROXY SAXAGLIPTIN; CARBON 14; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; GLUCURONIDE; PHENOBARBITAL; RIFAMPICIN; SAXAGLIPTIN; SULFATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLISM; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84862665119     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045450     Document Type: Article

References (18)

1. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, et al. (2005) Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:5025-5037.
2. Boulton DW and Geraldes M (2007) Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects. Diabetes 56:A161.
3. Cao K, Bonacorsi SJ Jr, Balasubramanian B, Hanson RL, Manchand P, Godfrey JD Jr, Fox R, Christopher LJ, Su H, and Iyer R (2007) Carbon-14 labeling of saxagliptin (BMS-477118). J Label Compd Radiopharm 50:1224-1229.
4. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, et al. (2008) Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36:1357-1364.
5. Fura A, Khanna A, Vyas V, Koplowitz B, Chang SY, Caporuscio C, Boulton DW, Christopher LJ, Chadwick KD, Hamann LG, et al. (2009) Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 37:1164-1171.
6. Gallwitz B (2008) Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs 11:906-917.
7. Gorrell MD (2005) Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 108:277-292.
8. Hong H, Su H, Ma L, Yao M, Iyer RA, Humphreys WG, and Christopher LJ (2011) In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor. Drug Metab Dispos 39:1658-1667.
9. Jones GS, Savage SA, Ivy S, Benitez PL, and Ramirez A (2011) Kinetic and mechanistic insight into the thermodynamic degradation of saxagliptin. J Org Chem 76:10332-10337.
10. Kania DS, Gonzalvo JD, and Weber ZA (2011) Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clin Ther 33:1005-1022.
11. Kieffer TJ and Habener JF (1999) The glucagon-like peptides. Endocr Rev 20:876-913.
12. McIntosh CH, Demuth HU, Pospisilik JA, and Pederson R (2005) Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 128:159-165.
13. Patel CG, Li L, Girgis S, Kornhauser DM, Frevert EU, and Boulton DW (2011) Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol 3:13-25.
14. Scheen AJ (2012) A review of gliptins in 2011. Expert Opin Pharmacother 13:81-99.
15. Upreti VV, Boulton DW, Li L, Ching A, Su H, Lacreta FP, and Patel CG (2011) Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase- 4 inhibitor, in healthy subjects. Br J Clin Pharmacol 72:92-102.
16. Wsól V, Skálová L, and Szotáková B (2004) Chiral inversion of drugs: coincidence or principle? Curr Drug Metab 5:517-533.
17. Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.
18. Xu X, Christopher LJ, Dueker S, Lohstroh P, Roongta V, Cojocaru L, Keung CF, Cao K, Bonasorsi S Jr, Humphreys WG, et al. (2011) Achieving regulatory approval: overcoming bioanalytical challenges in an onglyza micro-tracer absolute bioavailability study with accelerator mass spectrometry. 12th Annual Land O'Lakes Bioanalytical Conference; 2011 Jul 11-15; Merrimac, WI. University of Wisconsin School of Pharmacy, Extension Services in Pharmacy, Madison, WI.